The Nepalese Association of International NGOs (AIN) has urged to the international community for immediate assistance in addressing the countryR17;s health crisis, citing the fact that the oldest and most vulnerable people have not to receive the second dose of AstraZeneca vaccinations.
“This is likely to have a diminished effect on people who have been vaccinated, with far-reaching ramifications. This could have an influence on COVID-19 preventative measures and the government of Nepal’s efforts to immunize the populace, according to a statement released on Sunday.
According to an AIN press statement, “this is our sincere appeal to all G7 and other developed countries, as well as the European Union, to give AstraZeneca vaccines from their stockpile to Nepal to mitigate the humanitarian crisis.”
It stated that when distributing COVID-19 vaccines, the principle of equity must be followed to ensure that no one is denied access to the life-saving vaccines.
“This is only achievable with the help of the COVAX facility and vaccine-producing countries. “Effective diplomacy and transparent procurement and distribution processes are the only ways to ensure fair access to COVID-19 vaccines,” according to AIN.
While some rich countries have surplus vaccine supplies, underdeveloped countries have restricted access to vaccines, according to the report. Most affluent countries have vaccinated a large section of their populations, yet countries like Nepal are experiencing a severe vaccine shortage.
The number of cases recorded in Nepal has surpassed 0.65 million, with over 9,000 deaths reported. This data serves as a harsh reminder that Nepal urgently requires COVID-19 vaccines in order to save lives, limit the epidemic, and reduce the strain on the public health system if a third wave strikes, according to the statement.
According to the Ministry of Health and Population (MoHP), approximately 2.6 million people (9 percent of Nepal’s population) have gotten the first dosage of the vaccine, with another 0.7 million (3 percent) receiving the second dose.
More than 1.4 million patients who received the first doses of Covishield (Oxford AstraZeneca) vaccines in mid-March 2021 are still waiting for the second doses, even after 12 weeks.